Evaluation of the Anti-Oxidative Effects of Monocyte Cells Treated with Bone Marrow Mesenchymal Stem Cells Supernatant on Experimental Colitis in BALB/c Mice

  • Majdedin Ghalavand 1. Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2. Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran http://orcid.org/0000-0002-6134-9965
  • Hadi Esmaili Gouvarchin Ghaleh 2. Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
  • Bahman Jalali Kondori 3. Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran
  • Javad Razaviyan 4. Department of Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Samira Mohammadi-Yeganeh 5. Medical Nanotechnology and Tissue engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran 6. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Keywords: Monocyte, Mesenchymal Stem Supernatant, Colitis, BALB/c Mice


Background: Alternate activation of monocytes could induce anti-inflammatory impacts. This study aimed to investigate whether monocyte cells treated with bone marrow mesenchymal stem cells supernatant (MSC-Sp) could improve anti-inflammatory responses as a cell transfer therapy for colitis. Materials and Methods: The induction of experimental colitis was done by acetic acid in four groups of male BALB/c mice, including the control colitis, treated-monocytes, non-treated-monocytes, and mesalazine groups. Following MSCs culture, the supernatant was harvested, and then 50% conditioned media, or negative control media was added to the monocytes for 24 h. After ten days, peritoneal injection of treated or non-treated-monocytes (105 cells/100µL) was performed in animals' relevant groups of colitis. Ten days later, the oxidative stress profile and histopathological evaluation of colon tissue were assessed. Results: Treated monocytes showed a significant improvement in the oxidative stress profile, namely myeloperoxidase (0.126±0.008), nitric oxide (0.153±0.01), and malondialdehyde (0.148±0.014) compared to the control colitis group (P<0.05). Also, histopathological results revealed that the rate of damage in the treated-monocytes group was less than in normal mice. Conclusion: Our study indicated that the treated monocytes had anti-oxidative potential in colitis mice and were usable as a complementary therapy. [GMJ.2021;10:e2131]


Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(6):1280-90.



Corridoni D, Antanaviciute A, Gupta T, Fawkner-Corbett D, Aulicino A, Jagielowicz M, et al. Single-cell atlas of colonic CD8+ T cells in ulcerative colitis. Nat Med. 2020;26(9):1480-90.



Nanki K, Fujii M, Shimokawa M, Matano M, Nishikori S, Date S, et al. Somatic inflammatory gene mutations in human ulcerative colitis epithelium. Nature. 2020;577(7789):254-9.



Zhou X-L, Yang J, Qu X-J, Meng J, Miao R-R, Cui S-X. M10, a myricetin-3-ObD-Lactose sodium salt, prevents ulcerative colitis through inhibiting necroptosis in mice. Front Pharmacol. 2020;11:557312.


PMid:33041798 PMCid:PMC7517943

Wan S, Wu Q, Ji Y, Fu X, Wang Y. Promotion of the immunomodulatory properties and osteogenic differentiation of adipose‐derived mesenchymal stem cells in vitro by lentivirus‐mediated mir‐146a sponge expression. J Tissue Eng Regen Med. 2020;14(11):1581-91.



Cao C, Tarlé S, Kaigler D. Characterization of the immunomodulatory properties of alveolar bone-derived mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):1-13.


PMid:32138791 PMCid:PMC7059346

Liu H, Li R, Liu T, Yang L, Yin G, Xie Q. Immunomodulatory Effects of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Rheumatoid Arthritis. Front Immunol. 2020;11:1912.


PMid:32973792 PMCid:PMC7468450

Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998-1002.


PMid:34676125 PMCid:PMC7108005

Esmaili Gourvarchin Galeh H, Meysam Abtahi Froushani S, Afzale Ahangaran N, Hadai SN. Effects of Educated Monocytes with Xenogeneic Mesenchymal Stem Cell-Derived Conditioned Medium in a Mouse Model of Chronic Asthma. Immunol Invest. 2018;47(5):504-20.



Abtahi Froushani SM, Mashhouri S. The Effect of Mesenchymal Stem Cells Pulsed with 17 Beta-Estradiol in an Ameliorating Rat Model of Ulcerative Colitis. Zahedan Journal of Research in Medical Sciences. 2019.


Mashhouri S, Meysam Abtahi Froushani S, Asghar Tehrani A. Non-Adherent Bone Marrow-Derived Mesenchymal Stem Cells Ameliorate Clinical Manifestations and Inflammation in an Experimental Model of Ulcerative Colitis in Rats.IJIMS. 2020;45(5):341-51.

Song N, Scholtemeijer M, Shah K. Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends Pharmacol Sci. 2020;41(9):653-64.


PMid:32709406 PMCid:PMC7751844

Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. Cells. 2019;8(12):1605.


PMid:31835680 PMCid:PMC6952783

Randhawa PK, Singh K, Singh N, Jaggi AS. A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol. 2014;18(4):279-88.


PMid:25177159 PMCid:PMC4146629

Piechota-Polanczyk A, Fichna J. Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(7):605-20.


PMid:24798211 PMCid:PMC4065336

Kurutas EB, Cetinkaya A, Bulbuloglu E, Kantarceken B. Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis. Mediators Inflamm. 2005;2005(6):390-4.


PMid:16489261 PMCid:PMC1533903

Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells. 2014;6(5):552-70.


PMid:25426252 PMCid:PMC4178255

Yi T, Song SU. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res. 2012;35(2):213-21.



Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126-67.


PMid:23991888 PMCid:PMC3929010

MacDonald ES, Barrett JG. The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses. Front Vet Sci. 2019;6:507.


PMid:32039250 PMCid:PMC6985200

Melief SM, Geutskens SB, Fibbe WE, Roelofs H. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica. 2013;98(6):888-95.


PMid:23349310 PMCid:PMC3669444

Stavely R, Nurgali K. The emerging antioxidant paradigm of mesenchymal stem cell therapy. Stem Cells Transl Med. 2020;9(9):985-1006.


PMid:32497410 PMCid:PMC7445024

How to Cite
Ghalavand, M., Esmaili Gouvarchin Ghaleh, H., Jalali Kondori, B., Razaviyan, J., & Mohammadi-Yeganeh, S. (2021). Evaluation of the Anti-Oxidative Effects of Monocyte Cells Treated with Bone Marrow Mesenchymal Stem Cells Supernatant on Experimental Colitis in BALB/c Mice. Galen Medical Journal, 10, e 2131. https://doi.org/10.31661/gmj.v10i0.2131
Original Article